NVO
Novo Nordisk A/SClose $45.07EOD onlyThis page reflects NVO options positioning from the latest published market-close snapshot. Intraday price and contract changes are not displayed.
Consensus-supported lens with chain history and key metrics in the rail.
Earnings Verdict
Earnings expected around May 6th, 36 days out. IV is elevated (53%) with a clear term structure kink at the May 8th expiration, indicating earnings pricing. The expected move is ±9.8% ($33.14-$40.36) for the May 1st cycle. Historical data shows a strong beat rate but limited move history. The high IV and bearish flow regime favor premium-selling strategies, but the trending gamma and elevated VIX environment add risk.
Regime Classification
Earnings Overview
Next earnings: 2026-05-06 (36 days)explicit
Expected moves:
- 5/01 (31d): ±$3.61 (9.8%) [$33.14 - $40.36]
- 5/08 (38d): ±$4.75 (12.9%) [$32.00 - $41.51]
IV Setup
Term structure: Sharp kink at 5/08 (52.0% IV) vs 43.2% on 5/01 and 51.3% on 5/15. Elevated IV across the curve.
Crush estimate: ~15-20 vol pts post-earnings, back to ~35%
Skew: Bearish flow (net prem -$82M) and high P/C volume ratio (1.50) suggest put skew.
Historical Context
Historical earnings data not available.
Key Levels
Flow Highlights
Massive bearish premium flow in OTM puts ($65P: -$34.9M net, $60P: -$22.9M net, $50P: -$13.7M net)
Likely large-scale hedging or bearish bets far OTM, not directly tied to earnings EM.
Unusual $65P 4/17 volume (10k vs 1,250 OI) at 131% IV
Speculative or hedging activity for a sharp, near-term drop.
Strategies
Risk Assessment
What to Watch
Each report translates the same market-close options snapshot into a specific lens such as directional bias, premium-selling posture, flow quality, or earnings setup.
Reports are most useful for narrowing the playbook, surfacing entry and risk context, and deciding which raw data page to inspect next.
These are interpretation layers, not execution guarantees. Validate the setup against chain liquidity, expected move, and exposure before sizing risk.